Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Accured Expenses: 2012-2024

Historic Change in Accured Expenses for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $1.5 million.

  • Theravance Biopharma's Change in Accured Expenses rose 391.95% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 521.98%. This contributed to the annual value of $1.5 million for FY2024, which is 120.69% up from last year.
  • As of FY2024, Theravance Biopharma's Change in Accured Expenses stood at $1.5 million, which was up 120.69% from -$7.1 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Change in Accured Expenses ranged from a high of $6.0 million in FY2020 and a low of -$37.2 million during FY2021.
  • Over the past 3 years, Theravance Biopharma's median Change in Accured Expenses value was -$7.1 million (recorded in 2023), while the average stood at -$6.6 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first slumped by 722.18% in 2021, then spiked by 120.69% in 2024.
  • Over the past 5 years, Theravance Biopharma's Change in Accured Expenses (Yearly) stood at $6.0 million in 2020, then tumbled by 722.18% to -$37.2 million in 2021, then skyrocketed by 62.16% to -$14.1 million in 2022, then surged by 49.63% to -$7.1 million in 2023, then soared by 120.69% to $1.5 million in 2024.